Dr. David Carbone outlined lung cancer treatment advances from 1990–2022, with survival gains from chemo, targeted therapy, and immunotherapy. He cited ALK-targeted success and 20–21% five-year survival with immunotherapy. Emphasis was placed on early detection and future cures for driver mutations.